Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO
NCT ID: NCT01624571
Last Updated: 2013-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
147 participants
INTERVENTIONAL
2012-03-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects and Safety of Metronidazole in Patients With Gastrectomy
NCT01658852
Antiperistaltic Effect and Safety of Glycopyrronium for Colonoscopic Polypectomy
NCT06041984
Cold Snare Versus Double Biopsy Polypectomy Technique for Removal of Diminutive Colorectal Polyps
NCT01646242
Validation of Clinical Efficacy and Development of New Diagnostic Algorithm of Probe-based Confocal Laser Endomicroscopy in Patients With Lower Gastrointestinal Disorder
NCT02091895
Endoscopic Full Thickness Resection in the Lower GI Tract With the "Full Thickness Resection Device"
NCT02362126
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
300mg/day
LD02GIFRO
comparison of different dosages of drug
Group 2
600mg/day
LD02GIFRO
comparison of different dosages of drug
Group 3
900mg/day
LD02GIFRO
comparison of different dosages of drug
Placebo
Control Group
LD02GIFRO
comparison of different dosages of drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LD02GIFRO
comparison of different dosages of drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is scheduled for a partial colon resection with primary anastomosis via laparotomy
* Subject is scheduled to receive primary postoperative pain management with intravenous patient-controlled analgesia (PCA) opioids
Exclusion Criteria
* Subject has complete bowel obstruction
* Subject is scheduled for laparoscopic surgery
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LG Life Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan medical center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LG-GRCL001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.